The resistance mechanisms of proteasome inhibitor bortezomib

Citations of this article
Mendeley users who have this article in their library.

This article is free to access.


The proteasome inhibitor, bortezomib, a boronic dipeptide which reversibly inhibit the chymotrypsin-like activity at the β5-subunit of proteasome (PSMB5), has marked efficacy against multiple myeloma and several non-Hodgkin's lymphoma subtypes, and has a potential therapeutic role against other malignancy diseases. However, intrinsic and acquired resistance to bortezomib may limit its efficacy. In this article, we discuss recent advances in the molecular understanding of bortezomib resistance. Resistance mechanisms discussed include mutations of PSMB5 and the up-regulation of proteasome subunits, alterations of gene and protein expression in stress response, cell survival and antiapoptotic pathways, and multidrug resistance. © 2013 Lü and Wang; licensee BioMed Central Ltd.




Lü, S., & Wang, J. (2013, March 1). The resistance mechanisms of proteasome inhibitor bortezomib. Biomarker Research. BioMed Central Ltd.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free